Search

Your search keyword '"Reguiai, Ziad"' showing total 204 results
Start Over Author "Reguiai, Ziad"
204 results on '"Reguiai, Ziad"'

1. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials

Author

Lynde, Charles, Guenther, Lyn, Sauder, Maxwell, Bissonnette, Robert, Rao, Jaggi, Day, Isaiah, Devani, Alim, Metelitsa, Andrei, Grewal, Parbeer, Molin, Sonja, Ruer-Mulard, Mireille, Giordano-Labadie, Françoise, Maillard, Hervé, Reguiai, Ziad, Bernier, Claire, Leleu, Camille, Seneschal, Julien, Staumont-Sallé, Delphine, Hubiche, Thomas, Jacobzone, Caroline, Khemis, Abdallah, Crépy, Marie-Noëlle, Worm, Margitta, Bauer, Andrea, Sell, Sabine, Ekanayake-Bohlig, Swarna, Pauser, Sylvia, Buhl, Timo, Schwinn, Andreas, Eberlein, Bernadette, Quist, Sven, Bauer, Boris, Peris, Ketty, Rossi, Maria Teresa, Fargnoli, Maria, Naldi, Luigi, Stingeni, Luca, Ferrucci, Silvia, Walecka-Herniczek, Irena, Krasowska, Dorota, Lesiak, Aleksandra, Okuniewska, Aleksandra, Pulka, Grażyna, Dyczek, Malgorzata, Kwiek, Bartlomiej, Czajkowski, Rafal, Myśliwiec, Hanna, Mohandas, Padma, Cliff, Sandeep, Warren, Richard, Cousen, Pippa, Johnston, Graham, Woolf, Richard, Papp, Kim, Adam, David, Toth, Darryl, Hong, Chih-ho, Turchin, Irina, Niakosari, Firouzeh, Poulos, Elena, Rivers, Jason, Ohayon, Jason, Gooderham, Melinda, Tjioe, Milan, Rustemeyer, Thomas, de Bruin-Weller, Marjolein S., Schuttelaar, Marie L.A., Molhoek, Judith, Oosting, Bert, Pinter, Andreas, Kaspari, Markus, Magnolo, Nina, Sebastian, Michael, Thaci, Diamant, Schliemann, Sibylle, Radny, Peter, Leitz, Nicolas, Tsianakas, Athanasios, Yazdi, Amir, Kamstrup, Maria, Sommerlund, Mette, Zachariae, Claus, Owczarek, Witold, Dudra-Jastrzebska, Monika, Reich, Adam, Kowalska-Oledzka, Elzbieta, Szepietowski, Jacek, Poznanska, Maria, Weglowska, Jolanta, Aerts, Olivier, Roquet-Gravy, Pierre-Paul, Lanssens, Sven, Castelijns, Francisca, Scheers, Christelle, Suys, Erwin, Kint, Bernard, Serra-Baldrich, Esther, Carrascosa, José Manuel, de la Cueva Dobao, Pablo, Izu, Rosa, Silvestre, Juan Francisco, Coto-Segura, Pablo, Fernández-Orland, Almudena, Warren, Richard B, Agner, Tove, Schuttelaar, Marie L A, Baranowski, Keith, Korn, Sofie, Kurvits, Merle, Plohberger, Ursula, and Strange Vest, Natacha

Published
2024
Full Text
View/download PDF

2. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials

Author

Kimball, Alexa B, Jemec, Gregor B E, Alavi, Afsaneh, Reguiai, Ziad, Gottlieb, Alice B, Bechara, Falk G, Paul, Carle, Giamarellos Bourboulis, Evangelos J, Villani, Axel P, Schwinn, Andreas, Ruëff, Franziska, Pillay Ramaya, Larisha, Reich, Adam, Lobo, Ines, Sinclair, Rodney, Passeron, Thierry, Martorell, Antonio, Mendes-Bastos, Pedro, Kokolakis, Georgios, Becherel, Pierre-Andre, Wozniak, Magdalena B, Martinez, Angela Llobet, Wei, Xiaoling, Uhlmann, Lorenz, Passera, Anna, Keefe, Deborah, Martin, Ruvie, Field, Clarice, Chen, Li, Vandemeulebroecke, Marc, Ravichandran, Shoba, and Muscianisi, Elisa

Published
2023
Full Text
View/download PDF

3. Evolution of dupilumab‐associated conjunctivitis in patients with atopic dermatitis after switching dupilumab to tralokinumab or Janus kinase inhibitors (RESO‐ADOC study)

Author

Reguiai, Ziad, Becherel, Pierre André, Perrot, Jean Luc, Boulard, Claire, Fougerousse, Anne Claire, Begon, Edouard, Badaoui, Antoine, Poreaux, Claire, Parier, Josiane, Liegeon, Anne‐Laure, Levavasseur, Matthieu, Bing, Anne‐Claire, Estève, Eric, and Maccari, François

Subjects
*ATOPIC dermatitis, *DUPILUMAB, *ALLERGIC conjunctivitis, *CONJUNCTIVITIS, *MULTIVARIATE analysis, *CLINICAL trials
Abstract

Background Objectives Methods Results Conclusions Clinical trials and real‐life data have reported an increased incidence of conjunctivitis in patients treated with dupilumab for their atopic dermatitis (AD). Although mostly mild in severity, in some cases conjunctivitis will appear or increase after dupilumab initiation, which can lead to dupilumab discontinuation.(1) To describe the characteristics of patients developing conjunctivitis requiring discontinuation of dupilumab; and (2) to analyse the factors associated with a complete conjunctivitis improvement after dupilumab discontinuation and a switch to tralokinumab or Janus kinase inhibitors.This was a multicentre retrospective cohort study that included all patients with AD treated with dupilumab who developed conjunctivitis leading to dupilumab discontinuation and switching to tralokinumab or Janus kinase inhibitors in daily practice. Data on patients, their AD and conjunctivitis were analysed at the inclusion visit (corresponding to discontinuation of dupilumab and the institution of new AD treatment), at visit 2 (3–6 months after inclusion) and at visit 3 (corresponding to the last medical visit).After multivariate analysis, the only factors associated with a complete resolution of dupilumab‐associated conjunctivitis at visit 2 and/or visit 3 were conjunctivitis duration (OR 8.98, 95% CI 1.47–55) (p = 0.018), personal history of asthma (OR 10.66, 95% CI 1.82–62.63) (p = 0.009) and switching from dupilumab to Janus kinase inhibitors (OR 17.11, 95% CI 2.94–99.66) (p = 0.002).Although uncommon, severe dupilumab‐associated conjunctivitis is more frequent in daily life compared to its incidence in the dupilumab pivotal trials. In these cases, our study suggests that a rapid switch to another molecule, particularly a Janus kinase inhibitor, should be considered. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Impact of Baricitinib on Patients’ Quality of Life after One Year of Treatment for Atopic Dermatitis in Real-World Practice: Results of the Observatory of Chronic Inflammatory Skin Diseases Registry

Author

Reguiai, Ziad, primary, Becherel, Pierre André, additional, Perrot, Jean Luc, additional, Fougerousse, Anne Claire, additional, Begon, Edouard, additional, Poreaux, Claire, additional, Boulard, Claire, additional, Chaby, Guillaume, additional, Fite, Charlotte, additional, Zaraa, Inès, additional, Lons-Danic, Dominique, additional, Liegeon, Anne-Laure, additional, Parier, Josiane, additional, Quiles-Tsimaratos, Nathalie, additional, David, Laurene, additional, and Maccari, François, additional

Published
2023
Full Text
View/download PDF

8. Evaluation of Children with Psoriasis from the BiPe Cohort: Are Patients Using Biotherapies in Real Life Eligible for Phase III Clinical Studies?

Author

Phan, Céline, Beauchet, Alain, Burztejn, Anne-Claire, Severino-Freire, Maëlla, Mazereeuw-Hautier, Juliette, Barbarot, Sébastien, Girard, Céline, Lasek, Audrey, Reguiai, Ziad, Abasq, Claire, Sassolas, Bruno, Droitcourt, Catherine, Perrussel, Marc, Hadj-Rabia, Smail, Mallet, Stéphanie, Phan, Alice, Lacour, Jean-Philippe, Bourrat, Emmanuelle, Aubin, François, Mahé, Emmanuel, and for the Groupe de Recherche de la Société Française de Dermatologie Pédiatrique, and the Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie

Published
2019
Full Text
View/download PDF

9. Psychometric validation of a patient-reported outcome questionnaire (Qualipsosex) assessing the impact of psoriasis and psoriatic arthritis on patient perception of sexuality

Author

Lespessailles, Eric, Mahé, Emmanuel, Reguiai, Ziad, Begon, Edouard, Maccari, François, Beneton, Nathalie, Chaby, Guillaume, Rosenberg, Carole, Dernis, Emmanuelle, Roux, Fabienne, Henry-Desailly, Isabelle, Charles, Bénédicte, Ferdynus, Cyril, Marty, Marc, and Esteve, Eric

Published
2021
Full Text
View/download PDF

12. Patient-reported well-being in value-based care using tildrakizumab in a real-world setting: protocol of a multinational, phase IV, 1-cohort prospective observational study (the POSITIVE study)

Author

Augustin, Matthias, primary, Sommer, Rachel, additional, Daudén, Esteban, additional, Laws, Philip, additional, de Jong, Elke, additional, Fabbrocini, Gabriella, additional, Naldi, Luigi, additional, Navarini, Alexander, additional, Lambert, Jo, additional, Reguiai, Ziad, additional, Gerdes, Sascha, additional, Massana, Eric, additional, Obis, Teresa, additional, Kasujee, Ismail, additional, and Mrowietz, Ulrich, additional

Published
2023
Full Text
View/download PDF

13. Treatment of dissecting cellulitis of the scalp with tumour necrosis factor inhibitors: a retrospective multicentre study

Author

Alzahrani, Muslih, primary, Coste, Victor, additional, Konstantinou, Maria Polina, additional, Reguiai, Ziad, additional, Villani, Axel , additional, Hotz, Claire , additional, Viguier, Manuelle, additional, Pruvost-Balland, Christelle, additional, Dupuy, Alain, additional, Wolkenstein, Pierre , additional, Brun, Aurore, additional, Aubin, François, additional, and Sérézal, Irène Gallais, additional

Published
2023
Full Text
View/download PDF

16. Development of monoclonal gammopathy under biotherapy in psoriasis: a French multicenter retrospective study

Author

Liegeon, Anne-Laure, Mahe, Emmanuel, Begon, Edouard, Poreaux, Claire, Barbaud, Annick, Esteve, Eric, Quiles-Tsimaratos, Nathalie, Avenel-Audran, Martine, Schoeffler, Amélie, Mery-Bossard, Laure, Pauwels, Christine, Girard, Céline, Maillard, Hervé, Barthelme, Dominique, Bernier, Claire, Chaby, Guillaume, Reguiai, Ziad, Nguyen-Thi, Phi Linh, Maccari, François, and Schmutz, Jean-Luc

Published
2016
Full Text
View/download PDF

17. Contraception, Sexuality and Pregnancy in Women with Psoriasis: Real-Life Experience of 235 Women

Author

Maccari, François, Fougerousse, Anne Claire, Reguiai, Ziad, and Taieb, Charles

Subjects
childbearing, Clinical, Cosmetic and Investigational Dermatology, psoriasis, women, Original Research
Abstract

François Maccari,1,2 Anne Claire Fougerousse,2,3 Ziad Reguiai,2,4 Charles Taieb5,6 1Private Practice, La Varenne St Hilaire, Paris, France; 2Reso Pso, Dermatologist Network, Paris, France; 3Military Teaching Hospital Bégin, Saint Mandé, Paris, France; 4Service De Dermatologie, Polyclinique Courlancy, Reims, France; 5FIMARAD, Hôpital Necker Enfants Malades, Paris, France; 6European Market Maintenance Assessment, Vincennes, Paris, FranceCorrespondence: Charles Taieb Email charles.taieb@emma.clinicBackground: Little is known about how women of childbearing age with psoriasis experience contraception, sexuality and pregnancies through the lens of their skin condition.Objective: To evaluate the experiences and expectations in this group of patients.Materials and Methods: In total, 235 women aged between 18 and 45 years old completed an online survey. We collected the characteristics of psoriasis, contraception and pregnancy history. Psoriasis severity was measured using the Simplified Psoriasis Index. Patient quality of life was assessed using the Dermatology Life Quality Index (DLQI) and the Short Form-12.Results: Psoriasis was mild in 78% of cases. The mean DLQI score was 8.8, highlighting a moderate impact of psoriasis. In total, 28% of the women had no current follow-ups, while at least two distinct physicians followed 21% of these patients. In total, 31.5% of the women felt that they could discuss sexuality during their consultations. In addition, 63% of respondents had a contraceptive method, but more than half of the women reported that contraception was rarely or never discussed during the consultations. In total, 63% had at least one pregnancy, and 61.5% reported that the doctor managing their psoriasis did not discuss their pregnancy during consultations. Psoriasis worsened during pregnancy for 21% of the respondents but improved in 34%. Among women who were not pregnant, less than 15% reported that the doctor in charge of their psoriasis discussed family planning and pregnancy possibilities.Conclusion: Our study shows that the management of women of childbearing age with psoriasis must be improved with respect to sexuality, contraception and pregnancy planning.Keywords: psoriasis, women, childbearing

Published
2020

19. Recours aux médecines alternatives chez les patients adultes atteints de dermatite atopique – Cohorte Daphné

Author

Jacobzone Leveque, Caroline, primary, Reguiai, Ziad, additional, Fougerousse, Anne-Claire, additional, Maccari, François, additional, Badaoui, Antoine, additional, Esteve, Eric, additional, Perrot, Jean Luc, additional, Beaulieu, Domitille Thomas, additional, Begon, Edouard, additional, Delaunay, Juliette, additional, Pillette Delarue, Michelle, additional, Jouan, Nicole, additional, Jachiet, Marie, additional, Pallure, Valérie, additional, Beneton, Nathalie, additional, Parier, Josiane, additional, Misery, Laurent, additional, Fite, Charlotte, additional, and Mahe, Emmanuel, additional

Published
2021
Full Text
View/download PDF

20. Efficacité de l’abrocitinib chez les patients avec une atteinte prédominante de la tête et du cou dans les études JADE en monothérapie poolées

Author

Fougerousse, Anne-Claire, primary, Becherel, Pierre-André, additional, Reguiai, Ziad, additional, Maari, Catherine, additional, Roquet-Gravy, Pierre-Paul, additional, Dibonaventura, Marco, additional, Chan, Gary, additional, Bouhriche, Samir, additional, Clibborn, Claire, additional, Biswas, Pinaki, additional, and Lejeune, Alexandre, additional

Published
2021
Full Text
View/download PDF

21. Changements (« switchs ») de biothérapies dans le psoriasis de l’enfant : résultats de la cohorte BiPe

Author

Phan, Céline, primary, Beauchet, Alain, additional, reguiai, Ziad, additional, Severino-Freire, Maëlla, additional, Mazereeuw-Hautier, Juliette, additional, Bursztejn, Anne Claire, additional, Barbarot, Sébastien, additional, Hadj-Rabia, Smaïl, additional, Girard, Céline, additional, Phan, Alice, additional, Lacour, Jean Philippe, additional, Lasek, Audrey, additional, Brenaut, Emilie, additional, Perrussel, Marc, additional, Mallet, Stéphanie, additional, Piram, Maryam, additional, Fougerousse, Anne-Claire, additional, Barthélémy, Hugues, additional, Balguérie, Xavier, additional, and Mahé, Emmanuel, additional

Published
2021
Full Text
View/download PDF

22. Tolérance et efficacité du traitement du psoriasis par biothérapies ou aprémilast en cas d’antécédent d’hémopathie maligne : étude multicentrique rétrospective

Author

Cohen-Sors, Raphaella, primary, Chaby, Guillaume, additional, Fougerousse, Anne-Claire, additional, Maccari, François, additional, Roussel, Aude, additional, Reguiai, Ziad, additional, Mahe, Emmanuel, additional, Amy de la Breteque, Maud, additional, Delaunay, Juliette, additional, Cottencin, Anne-Caroline, additional, Bertolotti, Antoine, additional, and Kemp, Helene, additional

Published
2021
Full Text
View/download PDF

23. Efficacité et tolérance du dupilumab dans le traitement de la dermatite atopique de l’enfant de moins de 12 ans en vie courante : cohorte rétrospective multicentrique française

Author

Lasek, Audrey, primary, Bellon, Nathalia, additional, Mallet, Stéphanie, additional, Puzenat, Eve, additional, Bursztejn, Anne Claire, additional, Abasq, Claire, additional, Mazereeuw, Juliette, additional, Chiaverini, Christine, additional, Hubiche, Thomas, additional, Peyron, Nadia Raison, additional, Du Thanh, Aurélie, additional, Barbarot, Sébastien, additional, Aubert, Hélène, additional, Reguiai, Ziad, additional, Droitcourt, Catherine, additional, Fievet, Charlotte, additional, Bellissen, Astrid, additional, Bachelerie, Marie, additional, Nosbaum, Audrey, additional, Leymarie, Alicia, additional, Armingaud, Pierre, additional, and Mahé, Emmanuel, additional

Published
2021
Full Text
View/download PDF

24. Description de la dermatite atopique de l’adulte, résultats de la cohorte DAPHNE

Author

Leveque, Caroline Jacobzone, primary, Reguiai, Ziad, additional, Fougerousse, Anne Claire, additional, Maccari, Francois, additional, Badaoui, Antoine, additional, Esteve, Eric, additional, Perrot, Jean Luc, additional, Beaulieu, Domitille Thomas, additional, Begon, Edouard, additional, Delaunay, Juliette, additional, Delarue, Michelle Pillette, additional, Jouan, Nicole, additional, Jachiet, Marie, additional, Pallure, Valérie, additional, Beneton, Nathalie, additional, Parier, Josiane, additional, Misery, Laurent, additional, Fite, Charlotte, additional, Henry, Catherine Goujon, additional, Danic, Dominique Lons, additional, Bourrel, Magali, additional, Mery, Laure, additional, Abasq, Claire, additional, Salins, Claire Alice de, additional, Lepelley, Charlotte, additional, and Mahe, Emmanuel, additional

Published
2021
Full Text
View/download PDF

26. Dermatite atopique du sujet âgé. Cohorte Daphné

Author

Leveque, Caroline Jacobzone, primary, Reguiai, Ziad, additional, Fougerousse, Anne-Claire, additional, Maccari, François, additional, Badaoui, Antoine, additional, Esteve, Eric, additional, Perrot, Jean Luc, additional, Beaulieu, Domitille Thomas, additional, Begon, Edouard, additional, Delaunay, Juliette, additional, Delarue, Michelle Pillette, additional, Jouan, Nicole, additional, Jachiet, Marie, additional, Pallure, Valérie, additional, Beneton, Nathalie, additional, Parier, Josiane, additional, Fite, Charlotte, additional, Mery, Laure, additional, Abasq, Claire, additional, and Mahe, Emmanuel, additional

Published
2021
Full Text
View/download PDF

28. Dermatite atopique de l’adulte à type de prurigo – données de la cohorte Daphné

Author

Jacobzone Leveque, Caroline, primary, Reguiai, Ziad, additional, Fougerousse, Anne-Claire, additional, Maccari, François, additional, Badaoui, Antoine, additional, Esteve, Eric, additional, Perrot, Jean Luc, additional, Beaulieu, Domitille Thomas, additional, Begon, Edouard, additional, Delaunay, Juliette, additional, Pillette Delarue, Michelle, additional, Jouan, Nicole, additional, Jachiet, Marie, additional, Pallure, Valérie, additional, Beneton, Nathalie, additional, Parier, Josiane, additional, Misery, Laurent, additional, Fite, Charlotte, additional, Goujon Henry, Catherine, additional, Lons Danic, Dominique, additional, and Mahe, Emmanuel, additional

Published
2021
Full Text
View/download PDF

29. Severe androgenetic alopecia as a proxy of metabolic syndrome in male psoriatic patients older than 59 years

Author

Descamps, Vincent, Mahé, Emmanuel, Maccari, François, Begon, Edouard, Barthelemy, Hugues, Reguiai, Ziad, Bénéton, Nathalie, Estève, Eric, Chaby, Guillaume, Ruer-Mulard, Mireille, Steiner, Henry-Georges, Thomas-Beaulieu, Domitille, Avenel-Audran, Martine, Goujon-Henry, Catherine, Sigal, Michele-Lea, Ezzedine, Khaled, and Beauchet, Alain

Published
2014
Full Text
View/download PDF

31. Biological Therapies or Apremilast in the Treatment of Psoriasis in Patients with a History of Hematologic Malignancy: Results from a Retrospective Study in 21 Patients

Author

Cohen-Sors, Raphaella, primary, Fougerousse, Anne-Claire, additional, Reguiai, Ziad, additional, Maccari, Francois, additional, Mahé, Emmanuel, additional, Delaunay, Juliette, additional, Roussel, Aude, additional, de la Breteque, Maud Amy, additional, Cottencin, Caroline, additional, Bertolotti, Antoine, additional, Kemp, Hélène, additional, and Chaby, Guillaume, additional

Published
2021
Full Text
View/download PDF

37. Switching biologics in children with psoriasis: Results from the BiPe cohort.

Author

Phan, Céline, Beauchet, Alain, Reguiai, Ziad, Severino‐Freire, Maëlla, Mazereeuw‐Hautier, Juliette, Bursztejn, Anne‐Claire, Barbarot, Sébastien, Hadj‐Rabia, Smaïl, Girard, Céline, Phan, Alice, Lacour, Jean‐Philippe, Lasek, Audrey, Abasq, Claire, Brenaut, Emilie, Perrussel, Marc, Droitcourt, Catherine, Mallet, Stéphanie, Piram, Maryam, Fougerousse, Anne‐Claire, and Barthélémy, Hugues

Subjects
BIOLOGICALS, PSORIASIS, SURVIVAL rate, PEDIATRIC therapy, ETANERCEPT
Abstract

Background: There is currently little information on switching biologics in pediatric psoriasis. Objective: To evaluate the real‐world clinical practice and safety of switching biologics in the "Biological Treatments for Pediatric Psoriasis" (BiPe) cohort. Methods: Data for all 134 patients included in the BiPe cohort were analyzed. A further evaluation of the subpopulation of patients who switched from a first‐line biologic to a second‐line biologic was then conducted. Drug survival rates were also compared between biologics given as first‐line or second‐line agents. Results: Overall, 29 patients (female: 55%; mean age: 16.6 ± 3.0 years) switched between two biologics. Etanercept (ETN) was the first‐line biologic used in 23 patients: 16 (69.6%) switched to adalimumab (ADA) and seven (30.4%) to ustekinumab (UST). Six patients received first‐line ADA and switched to UST. Loss of efficacy (62.1%), primary inefficacy (20.7%), and parental choice (6.9%) were the main reasons for switching biologics. One (3.4%) of the switches was performed because of adverse events or intolerance. For UST and ADA, the 18‐month drug survival rate did not differ according to whether the agent was given as a first‐line or second‐line biologic (UST: P =.24; ADA: P =.68). No significant differences in drug survival rates were observed between the three different switches (ADA to UST, ETN to ADA, and ETN to UST). Conclusion: Our study provided key insights into the real‐life clinical practice of switching biologics in pediatric psoriasis patients. However, more information and guidance on switching biologics in pediatric psoriasis are needed to improve real‐life practice and outcomes. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

43. Cost-effectiveness of Emollients in the Prevention of Relapse among French Patients with Atopic Dermatitis.

Author

CABOUT, Elise, EYMERE, Sébastien, LAUNOIS, Robert, SEITÉ, Sophie, DELVIGNE, Véronique, TAÏEB, Charles, and REGUIAI, Ziad

Subjects
DISEASE relapse, ATOPIC dermatitis, COST effectiveness, MEDICAL care costs, MARKOV processes
Abstract

Atopic dermatitis affects up to 20% of children and quite frequently persists in adulthood. Follow-up, treatment, and prevention of relapses have an impact on healthcare spending. The aim of this study was to assess the cost-effectiveness of different emollients prescribed for patients with atopic dermatitis in France. A 3-health state Markov model was designed, using French data for resource utilization, price and transition probabilities. The effects of the use of 5 different emollients (A, B, C, D, E) or no emollient were compared. The selected outcome was time (years) without flare-up. The 5-year cost for emollient A is 1,575.64€, and the effectiveness is 3.89 years without flare-up. Strategy A is the most effective. Compared with treatment E, which was the least expensive emollient, A is more expensive (+481.84€) and more effective (0.082 years without flare-up). The incremental cost-effectiveness ratio is 5,877.48€/years without flare-up. In conclusion, treating atopic dermatitis with emollients is a cost-effective strategy. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

44. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort

Author

Faiz, Sarah, primary, Giovannelli, Jonathan, additional, Podevin, Céline, additional, Jachiet, Marie, additional, Bouaziz, Jean-David, additional, Reguiai, Ziad, additional, Nosbaum, Audrey, additional, Lasek, Audrey, additional, Ferrier le Bouedec, Marie-Christine, additional, Du Thanh, Aurélie, additional, Raison-Peyron, Nadia, additional, Tetart, Florence, additional, Duval-Modeste, Anne-Bénédicte, additional, Misery, Laurent, additional, Aubin, François, additional, Dompmartin, Anne, additional, Morice, Cécile, additional, Droitcourt, Catherine, additional, Soria, Angèle, additional, Arnault, Jean-Philippe, additional, Delaunay, Juliette, additional, Mahé, Emmanuel, additional, Richard, Marie-Aleth, additional, Schoeffler, Amélie, additional, Lacour, Jean-Philippe, additional, Begon, Edouard, additional, Walter-Lepage, Amélie, additional, Dillies, Anne-Sophie, additional, Rappelle-Duruy, Sandrine, additional, Barete, Stéphane, additional, Bellon, Nathalia, additional, Bénéton, Nathalie, additional, Valois, Aude, additional, Barbarot, Sébastien, additional, Sénéchal, Julien, additional, and Staumont-Sallé, Delphine, additional

Published
2019
Full Text
View/download PDF

47. Effectiveness and Safety of Anti-interleukin-17 Therapies in Elderly Patients with Psoriasis.

Author

PHAN, Céline, BENETON, Nathalie, DELAUNAY, Juliette, REGUIAI, Ziad, BOULARD, Claire, FOUGEROUSSE, Anne-Claire, CINOTTI, Elisa, ROMANELLI, Marco, MERY-BOSSARD, Laure, THOMAS-BEAULIEU, Domitille, PARIER, Josiane, MACCARI, François, PERROTI, Jean-Luc, RUER-MULARD, Mireille, BASTIEN, Marie, BEGON, Edouard, SAMIMI, Mahtab, JACOBZONE, Caroline, QUILES-TSIMARATOS, Nathalie, and DESCAMPS, Vincent

Subjects
OLDER patients, PSORIASIS, DISEASE relapse, THRUSH (Mouth disease), OLDER people
Abstract

Anti-interleukin-17 agents have recently been developed for the treatment of psoriasis. This study evaluated the tolerance and effectiveness of anti-interleukin-17 agents for psoriasis in elderly patients in daily practice. A multicentre, retrospective study was performed, involving psoriatic patients aged =65 years who had received an anti-interleukin-17 agent, including secukinumab, ixekizumab or brodalumab. A total of 114 patients were included: 72 received secukinumab, 35 ixekizumab, and 7 brodalumab. Treatment was stopped in 32 patients (28.9%), because of relapses in 14 patients (41.2%), primary failures in 11 patients (32.4%), or adverse events in 7 patients (20.6%). The 3 most frequently reported adverse events were injection site reactions (n = 4), oral candidiasis (n = 3), and influenza-like illness (n = 3). Regarding effectiveness, 80 patients (70%) reached a Physician Global Assessment score of 0/1, 6 months after treatment initiation. In conclusion, anti-interleukin-17 therapy appears to be an effective and safe therapeutic option for psoriasis treatment in patients aged = 65 years. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

48. Neurolymphomatosis associated with sezary syndrome

Author

Bezier, Maud, Reguiai, Ziad, Delaby, Philippe, Laroche, Liliane, Said, Gerard, Bernard, Philippe, and Grange, Florent

Subjects
Sezary syndrome -- Complications and side effects, Sezary syndrome -- Case studies, Mycosis fungoides -- Complications and side effects, Mycosis fungoides -- Case studies, Peripheral nerve diseases -- Development and progression, Peripheral nerve diseases -- Care and treatment, Peripheral nerve diseases -- Case studies, Health
Published
2009

49. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials

Author

Bissonnette, Robert, Warren, Richard B, Pinter, Andreas, Agner, Tove, Gooderham, Melinda, Schuttelaar, Marie L A, Crépy, Marie-Noëlle, Stingeni, Luca, Serra-Baldrich, Esther, Baranowski, Keith, Korn, Sofie, Kurvits, Merle, Plohberger, Ursula, Strange Vest, Natacha, Schliemann, Sibylle, Lynde, Charles, Guenther, Lyn, Sauder, Maxwell, Bissonnette, Robert, Rao, Jaggi, Day, Isaiah, Devani, Alim, Metelitsa, Andrei, Grewal, Parbeer, Molin, Sonja, Ruer-Mulard, Mireille, Giordano-Labadie, Françoise, Maillard, Hervé, Reguiai, Ziad, Bernier, Claire, Leleu, Camille, Seneschal, Julien, Staumont-Sallé, Delphine, Hubiche, Thomas, Jacobzone, Caroline, Khemis, Abdallah, Crépy, Marie-Noëlle, Worm, Margitta, Bauer, Andrea, Sell, Sabine, Ekanayake-Bohlig, Swarna, Pauser, Sylvia, Buhl, Timo, Schwinn, Andreas, Eberlein, Bernadette, Quist, Sven, Bauer, Boris, Peris, Ketty, Rossi, Maria Teresa, Fargnoli, Maria, Naldi, Luigi, Stingeni, Luca, Ferrucci, Silvia, Walecka-Herniczek, Irena, Krasowska, Dorota, Lesiak, Aleksandra, Okuniewska, Aleksandra, Pulka, Grażyna, Dyczek, Malgorzata, Kwiek, Bartlomiej, Czajkowski, Rafal, Myśliwiec, Hanna, Mohandas, Padma, Cliff, Sandeep, Warren, Richard, Cousen, Pippa, Johnston, Graham, Woolf, Richard, Papp, Kim, Adam, David, Toth, Darryl, Hong, Chih-ho, Turchin, Irina, Niakosari, Firouzeh, Poulos, Elena, Rivers, Jason, Ohayon, Jason, Gooderham, Melinda, Tjioe, Milan, Rustemeyer, Thomas, de Bruin-Weller, Marjolein S., Schuttelaar, Marie L.A., Molhoek, Judith, Oosting, Bert, Pinter, Andreas, Kaspari, Markus, Magnolo, Nina, Sebastian, Michael, Thaci, Diamant, Schliemann, Sibylle, Radny, Peter, Leitz, Nicolas, Tsianakas, Athanasios, Yazdi, Amir, Kamstrup, Maria, Sommerlund, Mette, Zachariae, Claus, Owczarek, Witold, Dudra-Jastrzebska, Monika, Reich, Adam, Kowalska-Oledzka, Elzbieta, Szepietowski, Jacek, Poznanska, Maria, Weglowska, Jolanta, Aerts, Olivier, Roquet-Gravy, Pierre-Paul, Lanssens, Sven, Castelijns, Francisca, Scheers, Christelle, Suys, Erwin, Kint, Bernard, Serra-Baldrich, Esther, Carrascosa, José Manuel, de la Cueva Dobao, Pablo, Izu, Rosa, Silvestre, Juan Francisco, Coto-Segura, Pablo, and Fernández-Orland, Almudena

Abstract

Chronic hand eczema is a fluctuating, inflammatory, pruritic, often painful disease of hands and wrists that strongly impacts quality of life and occupational capabilities of patients. The aim of phase 3 DELTA 1 and DELTA 2 was to assess the efficacy and safety of twice-daily applications of the topical pan-Janus kinase inhibitor delgocitinib cream 20 mg/g versus cream vehicle in adults with moderate to severe chronic hand eczema.

Published
2024
Full Text
View/download PDF

50. Real-World Effectiveness and Safety of Apremilast in Older Patients with Psoriasis.

Author

Phan, Céline, Beneton, Nathalie, Delaunay, Juliette, Reguiai, Ziad, Boulard, Claire, Fougerousse, Anne-Claire, Cinotti, Elisa, Romanelli, Marco, Mery-Bossard, Laure, Thomas-Beaulieu, Domitille, Parier, Josiane, Maccari, François, Chaby, Guillaume, Bastien, Marie, Begon, Edouard, Samimi, Mahtab, Prignano, Francesca, Beauchet, Alain, Mahé, Emmanuel, and for the GEM Resopso

Subjects
AGE distribution, MEDICAL cooperation, PATIENT safety, PSORIASIS, RESEARCH, THALIDOMIDE, TREATMENT effectiveness, RETROSPECTIVE studies, APREMILAST, DESCRIPTIVE statistics, OLD age
Abstract

Introduction: Apremilast is a drug recently developed for psoriasis. Few data are available on its use in the elderly. We evaluated the tolerance and effectiveness of apremilast used in daily practice for psoriasis treatment in older patients. Methods: We performed a multicenter, retrospective study involving patients aged ≥ 65 years who had received apremilast as a psoriasis treatment. Demographic data and details regarding psoriasis and adverse events (AEs) were collected from patient medical records. Results: 135 patients were included (mean age: 73.5 years). Treatment was stopped in 74 patients (54.8%) for AEs (n = 43, 56.6%), primary failures (n = 18, 23.4%), and relapses (n = 7, 9.2%). When patients were stratified by age at treatment initiation, the main cause of discontinuation in patients ≥ 75 years was AEs, whereas in patients aged 65–74 years it was primary failures (28.3%). Sixty-one patients reported AEs, mainly digestive (n = 49). Regarding effectiveness, 45.2% of patients reached PGA 0/1 between 3 and 6 months after treatment initiation. One-year apremilast continuation rates were better in the 65–74 and 75–84 years subgroups than in the > 85 years subgroup (p = 0.01). Conclusion: Apremilast seems to be an effective and safe therapeutic option for psoriasis in the elderly. The main AEs reported by patients did not seem to differ from those reported previously in younger populations. However, AEs were more frequent in patients > 75 years old leading to more frequent discontinuation of apremilast compared with younger patients, suggesting a higher level of vigilance is needed in the elderly. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results